Private Companies in ApicHope Pharmaceutical Co., Ltd (SZSE:300723) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 5.2% Last Week
Private Companies in ApicHope Pharmaceutical Co., Ltd (SZSE:300723) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 5.2% Last Week
Key Insights
主要見解
- ApicHope Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public
- 57% of the business is held by the top 2 shareholders
- Insiders own 19% of ApicHope Pharmaceutical
- 一品紅製藥公司的重要私人公司所有權表明,關鍵決策會受到來自更大公衆股東的影響。
- 前2名股東持有57%的業務
- 內部人員擁有一品紅製藥公司19%的股份。
If you want to know who really controls ApicHope Pharmaceutical Co., Ltd (SZSE:300723), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are private companies with 44% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
如果你想知道誰真正控制了一品紅製藥公司(SZSE:300723),那你需要看一下它持股註冊表的組成情況。擁有最大份額的群體是持有44%的私人公司。也就是說,如果股票上漲(或者出現下滑),這個群體將會獲得最大的利益(或者遭受最大的損失)。
As a result, private companies were the biggest beneficiaries of last week's 5.2% gain.
因此,私人公司成爲上週5.2%漲幅的最大受益者。
Let's delve deeper into each type of owner of ApicHope Pharmaceutical, beginning with the chart below.
讓我們深入了解一品紅製藥公司的每種所有者類型,從下面的圖表開始。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240712/0-776898561ffd96aed1728ae64c069b85-0-e2431b1af43facebfe38e58da6cd507f.png/big)
What Does The Institutional Ownership Tell Us About ApicHope Pharmaceutical?
機構持股關於一品紅製藥公司的信息。
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
機構通常在向自己的投資者報告時會針對一個基準進行衡量,因此一旦某隻股票被納入主要指數,他們通常會更加熱衷於該股票。我們預計大多數公司都會有一些機構在登記簿上,尤其是那些正在增長的公司。
ApicHope Pharmaceutical already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see ApicHope Pharmaceutical's historic earnings and revenue below, but keep in mind there's always more to the story.
Insider Ownership Of ApicHope Pharmaceutical
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240712/0-776898561ffd96aed1728ae64c069b85-1-6d822b72bbffc441293a7f7a8a735974.png/big)
We note that hedge funds don't have a meaningful investment in ApicHope Pharmaceutical. The company's largest shareholder is Guangdong Guangrun Group Co., Ltd., with ownership of 41%. In comparison, the second and third largest shareholders hold about 16% and 5.4% of the stock. Hanxiong Li, who is the second-largest shareholder, also happens to hold the title of Chief Executive Officer.
我們注意到,對於一品紅製藥公司,對沖基金沒有意義的投資。該公司最大的股東是廣東廣潤集團有限公司,持股比例爲41%。相比之下,第二大和第三大股東持有約16%和5.4%的股份。第二大股東李漢雄也恰好是首席執行官的職位。
A more detailed study of the shareholder registry showed us that 2 of the top shareholders have a considerable amount of ownership in the company, via their 57% stake.
股權登記簿的更詳細研究向我們表明,前兩大股東通過其擁有的57%股份在該公司擁有重大持股。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
儘管研究公司機構所有權數據是有意義的,但了解分析師的情緒也很有意義,以了解市場的走向。因爲有很多分析師正在跟蹤這個股票,所以看看他們的預測可能是值得的。
Insider Ownership Of ApicHope Pharmaceutical
一品紅製藥公司的內部人員擁有相當大的比例。它市值僅爲90億元人民幣,而內部人員則擁有自己名下17億元人民幣的股份。這是相當大的。大多數人會說這顯示了與股東的良好一致性,尤其是在這樣規模的公司中。你可以點擊此處看看這些內部人員是否一直在買賣。
The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
公司內部人員的定義可能是主觀的,並且在不同的司法管轄區之間是不同的。我們的數據反映了個別內部人員,至少捕捉到了董事會成員。公司管理業務,但首席執行官即使是董事會成員也必須向董事會負責。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。
It seems insiders own a significant proportion of ApicHope Pharmaceutical Co., Ltd. It has a market capitalization of just CN¥9.0b, and insiders have CN¥1.7b worth of shares in their own names. That's quite significant. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.
一品紅製藥公司的公衆股東,主要由個人投資者組成,擁有20%的所有權,對一品紅製藥公司產生了一定的影響力。雖然這種所有權的大小可能不足以影響他們的決策,但他們仍然可以對公司政策產生集體影響。
General Public Ownership
一般大衆所有權
With a 20% ownership, the general public, mostly comprising of individual investors, have some degree of sway over ApicHope Pharmaceutical. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
我們的數據顯示,私人公司持有公司股份的44%。從這個事實很難得出任何結論,因此應該研究這些私人公司的所有者是誰。有時,內部人員或其他相關方可能會通過單獨的私人公司擁有上市公司的股份。
Private Company Ownership
私有公司的所有權
Our data indicates that Private Companies hold 44%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
儘管考慮擁有一家公司的各個團體是值得的,但還有更重要的因素。例子就是:我們發現了一品紅製藥公司的4個警示信號,你應該注意一下。
Next Steps:
下一步:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 4 warning signs for ApicHope Pharmaceutical you should be aware of.
But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.
但最終,決定該業務所有者將獲得多大利益的是未來而非過去。因此,我們認爲最好查看此免費報告,以了解分析師是否預測更光明的未來。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。